SML3961

Paricalcitol

≥98% (HPLC)

• Synonyme(s) : (1R,3R)-5-((E)-2-((1R,3aS,7aR)-1-((2R,5S,E)-6-hydroxy-5,6-dimethylhept-3-en-2-yl)-7a-methyldihydro-1H-inden-4(2H,5H,6H,7H,7aH)-ylidene)ethylidene)cyclohexane-1,3-diol, (1alpha.3beta,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol, (7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1alpha,3beta,25-triol, 19-Nor-1alpha,25-dihydroxyvitamin D2
• Formule empirique (notation de Hill): C₂₇H₄₄O₃
• Numéro CAS: 131918-61-1
• Poids moléculaire : 416.64
• Code UNSPSC : 12352200
• Nomenclature NACRES : NA.77

Propriétés

• Niveau de qualité: 100
• Essai: ≥98% (HPLC)
• Forme: powder
• Couleur: white to beige
• Solubilité: DMSO: 2 mg/mL, clear
• Température de stockage: -10 to -25°C

Description

Actions biochimiques/physiologiques

Agonist for the calcitriol (Vitamin D receptor); Vitamin D analog; Antihyperparathyroid.

Paricalcitol is Vitamin D analog that acts as an agonist for the calcitriol receptor (Vitamin D receptor, VDR). It suppresses parathyroid hormone (PTH) gene transcription and PTH secretion and has been used clinically because of its antihyperparathyroid activity without inducing hypercalcemia or hyperphosphatemia. There is growing evidence that vitamin D either directly or indirectly affects cardiac structure and function. Paricalcitol showed improvement of cardiac function after myocardial infarction in mice with decreases in biomarkers, apoptosis, inflammation, and fibrosis.

Informations sur la sécurité

• Pictogrammes: GHS06,GHS08
• Mention d'avertissement: Danger
• Mentions de danger: H301 + H311,H330,H372
• Conseils de prudence: P260 - P264 - P280 - P302 + P352 + P312 - P304 + P340 + P310 - P314
• Classification des risques: Acute Tox. 2 Inhalation - Acute Tox. 3 Dermal - Acute Tox. 3 Oral - STOT RE 1 Oral
• Code de la classe de stockage: 6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
• Classe de danger pour l'eau (WGK): WGK 3
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable